BB-NCIPD

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Counteracting counterfeits in the pharmaceutical supply chain Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
  2. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity
  4. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  5. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Infection Control

Stablepharma and Bul Bio sign agreement on Tetanus diphtheria vaccine

This agreement means that Stablepharma can progress and lead full development and registration of dry, thermostable versions of the Tetadif vaccine, a WHO pre-approved vaccine for global distribution
Research & Development

Accelerating vaccine development with collaboration

BB-NCIPD (Bul Bio) and Stablepharma have recently entered into a partnership to produce the world’s first fridge-free tetanus diphtheria (Td) vaccine. And, having received very encouraging potency and accelerated thermostability data from animal challenge trials, Dr Kevin Robinson spoke to Mr Roumen Kofinov, MD, General Manager of Bul Bio, and Özgür Tuncer, CEO and Executive Director of Stablepharma, to find out more
Finance

Stablepharma and BB-NCIPD collaborating on Td vaccine

The companies are developing a version of BB-NCIPD’s Td vaccine using Stablepharma’s StabevaX technology
Subscribe now